title: Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study.
abstract: We compared the efficacy and adverse effects of antihypertensive drug regimens in 690 men past age 60 with diastolic blood pressure 90-114 mm Hg and systolic blood pressure less than 240 mm Hg. They received either a low (25-50 mg) or high (50-100 mg) dose of hydrochlorothiazide daily. Of 644 patients who completed the hydrochlorothiazide titration, 375 (58.2%) were responders (diastolic blood pressure less than 90 and less than or equal to 5 mm Hg below baseline) and 92.8% of these completed a 6-month maintenance period. Blood pressure was reduced from 157.6/98.5 mm Hg by 18.3/9.5 mm Hg with low dose hydrochlorothiazide and by 20.4/9.6 mm Hg with high dose hydrochlorothiazide; more patients achieved goal blood pressure with the high dose. Whites and blacks responded equally. Serum potassium less than 3.5 mmol/l occurred in 104 of 321 (32.3%) of the high dose versus 62 of 333 (18.6%) of the low dose hydrochlorothiazide patients. The 269 nonresponders to hydrochlorothiazide were randomly assigned in a double-blind study to receive hydralazine, methyldopa, metoprolol, or reserpine in addition to hydrochlorothiazide; 79.2% responded to the addition of the second drug and 87.3% of these completed a 6-month maintenance phase. Overall, there were no significant efficacy differences among the step 2 regimens. We conclude that the lower dose of hydrochlorothiazide was nearly as effective as the higher dose, and the addition of a second drug was effective and generally well tolerated in elderly patients.
authors.affiliation: Department of Veterans Affairs, Veterans Administration Medical Center, Miami, FL 33125.
authors.forename: B J
authors.initials: BJ
authors.lastname: Materson
authors.forename: W C
authors.initials: WC
authors.lastname: Cushman
authors.forename: G
authors.initials: G
authors.lastname: Goldstein
authors.forename: D J
authors.initials: DJ
authors.lastname: Reda
authors.forename: E D
authors.initials: ED
authors.lastname: Freis
authors.forename: E A
authors.initials: EA
authors.lastname: Ramirez
authors.forename: F N
authors.initials: FN
authors.lastname: Talmers
authors.forename: T J
authors.initials: TJ
authors.lastname: White
authors.forename: S
authors.initials: S
authors.lastname: Nunn
authors.forename: R H
authors.initials: RH
authors.lastname: Chapman
mesh_terms: D000368:Aged; D000375:Aging / Q000502:physiology; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006339:Heart Rate; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D011188:Potassium / Q000097:blood; D044469:Racial Groups
chemical_list: D000959:Antihypertensive Agents; D004232:Diuretics; D006852:Hydrochlorothiazide; D011188:Potassium